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to climb for the next several decades ( 5 ) . However, these models have not considered the changing prevalence of HCV and other risk factors ( 3 ) . Whether predicted models of HCC trends are accurate remains uncertain. To characterize trends in the United States in the early twenty-fi rst century, HCC incidence and liver cancer mortality rates were examined by demographic characteristics.
METHODS
Incidence
Cancer incidence data during 2000 -2010 were obtained from all 18 SEER registries, which cover 28 % of the US population ( 6 ) . Liver cancer incidence was defi ned by International Classifi cation of Diseases for Oncology, Th ird Edition ( 7 ) using topography codes C22.0 and C22.1. HCC cases were restricted to morphology codes 8170 -8175. Of the 87,988 malignant liver and intrahepatic cancer diagnoses reported during 2000 -2010 in SEER 18 registries, 63,735 (72 % ) were classifi ed as HCCs.
Mortality
Th e US data on cause of mortality during the years 2000 -2010 were reported by the Centers for Disease Control and Prevention, National Center for Health Statistics ( 8 ) . Deaths because of liver cancer were identifi ed by International Classifi cation for Diseases version 10 codes for the underlying cause of death ( 9 ) , using codes C22.0 -C22.9 (malignant neoplasm of liver and intrahepatic bile ducts), excluding C22.1 (intrahepatic bile duct cancer). To improve completeness of classifi cation, mortality rates among Hispanics and non-Hispanics were restricted to areas that met data quality measures for reporting of Hispanic ethnicity, thereby excluding the populations of New Hampshire, North Dakota, South Carolina, and Washington, DC, that account for ~ 2 % of the US population ( 10 ) . Th e current analysis was based on 138,326 reported liver cancer deaths, aft er excluding 27,203 intrahepatic bile duct cancer deaths. Sensitivity analyses of mortality trends that restricted cases and populations to SEER registry areas were performed.
Populations
Data on HCC incidence and liver cancer mortality were linked to Census Bureau population denominator data for 2000 through 2010, with data by geographic location, gender, age, and race / ethnicity (non-Hispanic white, black, Asian / Pacifi c Islander, and Hispanic) ( 11 ). American Indians / Alaska Natives were not included in the current study as small counts yielded unstable rate estimates.
Statistical analysis
Average annual HCC incidence and liver cancer mortality rates per 100,000 persons were estimated for the most recent 5-year period of diagnoses, 2006 -2010 (SEER * Stat v 7.0. 9, Information Management Services, Silver Spring, MD). Rates were age adjusted by the direct method to the 2000 US standard population (19 age groups) ( 12 ) . Rates and trends were examined by age group (overall, 35 -49, 50 -64, and 65 + years of age), gender, non-Hispanic race, and Hispanic ethnicity. Joinpoint regression ( 13 ) allowing two segments was used to fi t age-adjusted trends for 2000 -2010 (Joinpoint v 3.5, Information Management Services). Annual percent change (APC) was considered statistically signifi cant when the regression line slope diff ered from zero ( P < 0.05).
State-specifi c liver cancer mortality rates per 100,000 persons during 2006 -2010 were age adjusted by the direct method to the 2000 US standard population (19 age groups) ( 12 ) . We used the Jenks natural break classifi cation method ( 14 ) to map six categories: states with 2.3 -2.9 deaths per 100,000 (5 states), 3.0 -3.5 deaths per 100,000 (11 states), 3.6 -4.0 deaths per 100,000 (13 states), 4.1 to 4.5 deaths per 100,000 (12 states), 4.6 to 5.5 deaths per 100,000 (6 states), and 5.6 to 6.8 deaths per 100,000 (3 states and Washington, DC). State rates were compared with those for two underlying causes: diabetes mellitus and chronic liver diseases including cirrhosis.
Maps of liver cancer mortality rate trends for age groups 35 -49, 50 -64, and 65 + years, based on a single joinpoint segment model for the period 2000 -2010 categorized states into fi ve groups, based on criteria used in the National Cancer Institute ' s Cancer Trends Progress Report ( 15 ) . Group 1: signifi cant decrease (rate decreasing, statistically signifi cant APC); group 2: nonsignifi cant decrease (rate decrease more than 0.5 % per year, APC not statistically signifi cant); group 3: stable (absolute value of rate change 0.5 % per year, APC not statistically signifi cant); group 4: non signifi cant increase (rate increase >0.5 % per year, APC not statistically signifi cant); and group 5: signifi cant increase (Rate increasing with a statistically signifi cant APC). National mortality trends for two underlying causes of liver cancer (i) liver disease and cirrhosis and (ii) diabetes mellitus were compared with those for liver cancer. Using the fi ve-category trend variable, correlations with state-level mortality trends were examined with the CORR procedure (SAS v 9.3, Cary, NC). State-level maps of liver cancer mortality rates and trends were drawn using ArcMap 10.0 (ESRI, Redlands, CA).
RESULTS
HCC incidence
As shown in Table 1 , HCC incidence increased with age in all racial / ethnic groups in the interval 2006 -2010, with the exception of blacks, for whom rates were higher among individuals 50 -64 than 65 + years of age. All reported incidence rates are per 100,000 people. Overall, Asians and Pacifi c Islanders had the highest incidence rates, followed by Hispanics, blacks, and, last, whites. Among individuals aged 35 -49 years, Asians and Pacifi c Islanders had the highest HCC incidence rate (4.7), followed by Hispanics (3.2), blacks (2.5), and whites (1.4). Among individuals aged 50 -64 years, blacks had the highest incidence rate (26. HCC incidence trends by race, age, and gender are shown in Figure 2 with APCs presented in Supplementary Table 1 online. Age-and race-specifi c rates were higher among men than women. Signifi cantly increasing trends occurred only among Hispanics, whites, and black men and women aged 50 -64 and 65 + years, with the exception of a stable trend among Hispanic Table 3a . Sensitivity analyses restricted to SEER areas revealed mortality trends comparable to US patterns in both magnitude and statistical signifi cance (data not shown). Th e US liver cancer mortality trends by race, age, and gender are shown in Figure 3 with APCs presented in Supplementary Table 2 . Age-and race-specifi c rates were higher among men than women. Signifi cantly increasing trends occurred only among Hispanics and white and black men aged 50 -64 and 65 + years, Hispanic women aged 65 + years, and black and white women aged 50 -64 years. Mortality rates did not signifi cantly change for women in other population subgroups except for decreasing trends among black women aged 35 -49 years and Asian / Pacifi c Islander women aged 50 -64 years. Among men, mortality rates were stable for Asian / Pacifi c Islanders aged 50 -64 and 65 + years and signifi cantly decreased among Asians / Pacifi c Islanders, blacks, Hispanics, and white men aged 35 -49 years. APCs and confi dence intervals for these trends are presented in Table 3b .
State-specifi c liver cancer mortality rates
Figure 4 presents state-specifi c liver cancer mortality rates that ranged from 2.3 to 6.8. Th e highest rates (5.5 -6.8) were experienced by the populations of Washington, DC, and three
Liver cancer mortality
Between 2006 and 2010, the US liver cancer mortality rates increased with age in all racial / ethnic groups ( Table 1 ). All reported mortality rates are per 100,000 people. Among individuals aged 35 -49 years, Asians / Pacifi c Islanders had the highest mortality rates (2.8), followed by blacks (2.0), Hispanics (1.4), and whites (0.9). Among individuals aged 50 -64 years, blacks had the highest mortality rate (18.6), followed by Hispanics (13.5), Asians / Pacifi c Islanders (13.0), and whites (7.7). Mortality rates were highest among Asians / Pacifi c Islanders aged 65 + years (43.2 per 100,000).
As shown in Figure 1b , overall liver cancer mortality rates signifi cantly increased during 2000 -2010 (APC = 2.1 % ), with a less rapid increase among individuals aged 65 + years (APC = 1.1 % ) than among individualss aged 50 -64 years (APC = 5.6 % ). Th ere was a signifi cant decrease, however, among individuals aged 35 -49 years (APC = − 3.2 % ).
Th e US liver cancer mortality trends by race / ethnic group during 2000 -2010 are shown in Table 2b . Overall, rates signifi cantly increased during 2000 -2010 among whites, blacks, and Hispanics (2.1 % , 2.4 % , and 1.3 % per year, respectively); however, rates among Asians / Pacifi c Islanders signifi cantly decreased ( − 1.6 % per year). were seen ( Figure 5 ). Among individuals aged 35 -49 years, rates signifi cantly decreased in 12 states and nonsignifi cantly decreased in 23 states and Washington, DC, with no state experiencing a signifi cant increase ( Figure 5a ). In contrast, among individuals aged 50 -64 years, rates signifi cantly increased in 41 states and Washington, DC, with no state experiencing a signifi cant decrease ( Figure  5b ). Rates among individuals aged 65 + years signifi cantly increased in California, Arizona, Oklahoma, Florida, Georgia, Virginia, the District of Columbia, Delaware, New York, Vermont, and Massachusetts, and signifi cantly decreased in Alaska ( Figure 5c ). Table 5 presents national mortality trends for liver cancer and two underlying causes of liver cancer: (i) chronic liver disease and cirrhosis and (ii) diabetes mellitus. Th e direction of liver cancer mortality trends were consistent with those for chronic liver disease and cirrhosis in 35 -49-year-old individuals, for whom both causes of death signifi cantly decreased, and 50 -64-year-old individuals, for whom both causes of death signifi cantly increased. Th ere was also a statistically signifi cant correlation between the Gulf Coast states (Louisiana, Mississippi, and Texas). Th e second highest rates were reported in Alabama, Arkansas, California, Hawaii, Nevada, and New Mexico. Coastal, Appalachian, and Midwestern states generally reported higher rates than states in the Northern Plains and Northern Rocky Mountains. Confi dence intervals for these rates are presented in Table 4 .
Among the top 10 liver cancer death rate areas, only New Mexico was a top 10 state for mortality from both diabetes mellitus and chronic liver diseases. Five other states ranked in the top 10 for diabetes mellitus mortality (Louisiana, Arkansas, Mississippi, Alabama, and Washington, DC). Th ree more states were top 10 states for chronic liver disease mortality (California, Nevada, and Texas). Only Hawaii was in the bottom 10 for both underlying causes of mortality (data not shown).
State-specifi c liver cancer mortality trends
When state-specifi c liver cancer mortality trends during 2000 -2010 were examined by age group, striking age-specifi c patterns 
DISCUSSION
Aft er decades of statistically signifi cant increasing HCC incidence rates, during 2007 -2010 the trend was no longer statistically signifi cant. Th e change was partly explained by decreasing incidence rates among Asians / Pacifi c Islanders, the racial group most aff ected by HCC, and among men aged 35 -49 years. Incidence rates only increased among blacks, Hispanics, and white men and women aged 50 + years. Geographic variation in liver cancer mortality suggests a need for focused liver cancer control eff orts in southern and coastal states. Across states, increases in liver cancer mortality rates were most oft en seen among individuals aged 50 -64 years (baby-boomers) and decreasing rates occurred primarily among individuals in the next generation, aged 35 -49 years. Th ese fi ndings support the hypothesis that HCC incidence and liver cancer mortality trends vary across race, ethnicity, age, gender, and geographic groups.
HCC incidence trends are aff ected by the changing prevalence of risk factors. In the United States, an important risk factor is HCV infection ( 16 ) , particularly among individuals born between 1945 and 1965, commonly referred to as " baby-boomers " ( 17 ) . Other HCC risk factors include chronic hepatitis B virus infection ( 18 ) , obesity ( 19 ) , diabetes ( 20 ) , nonalcoholic fatty liver disease ( 21 ) , and excessive alcohol use ( 22 ) , all of which occur at variable frequencies across sociodemographic sectors of the population ( 23 -27 ) . Each of these factors predisposes to cirrhosis, the precursor of most HCC. Th is report found parallel age-specifi c mortality trends for liver cancer and chronic liver disease including cirrhosis and elevated mortality rates for diabetes mellitus or chronic liver disease in states with high liver cancer death rates. Th ese fi ndings should however be interpreted cautiously because in the past, individuals with cirrhosis tended to die from the disease. However, as treatment has improved, the risk of death from cirrhosis has declined and, as a consequence, the risk of HCC 
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Consistent with prior studies of HCC incidence in the United States, the continuing increase in the US liver cancer mortality rates was driven by increasing trends among blacks, whites, and Hispanics ( 4, 29, 30 ) . In this report, liver cancer mortality rates among adults aged 50 -64 years were signifi cantly higher for blacks than other racial / ethnic groups. Although not statistically signifi cant, for the fi rst time, Hispanics aged 50 -64 years had higher HCC incidence and liver cancer mortality rates than Asians / Pacifi c Islanders. Better estimates of the fraction of HCC cases in aff ected subgroups attributable to specifi c etiologies would facilitate screening of at-risk people.
Compared with other racial groups, liver cancer incidence historically has been elevated among Asians / Pacifi c Islanders. Th is is attributed to the high rate of chronic hepatitis B virus infection among older adults who were born outside the United States ( 16 ) . A previous report observed that liver cancer mortality rates among Asians / Pacifi c Islanders declined 0.9 % per year from 1992 to 2005 ( 4 ) . Th e present report found a more rapid rate of decline ( − 1.6 % ) during 2000 -2010. Cultural awareness of liver cancer risk may incentivize hepatitis B virus and liver cancer screening and related therapies in this racial group that will further decrease liver cancer mortality rates.
Declining liver cancer mortality rates among young adults aged 35 -49 years may signal a future decline in overall US liver cancer mortality rates. Th is was the case in Japan, where liver cancer mortality peaked a generation earlier than in the United States among the Japanese birth cohort born during 1925 -1939 ( 35,36 ) . A decrease in Japanese liver cancer mortality began around 1985, and was fi rst evident in the sentinel group of young adults ~ 40 years of age ( 36 ) . Th e reversal of liver cancer mortality trends in Japan has been attributed to declining exposure to HCV-related risk factors that included injected drug use and contaminated blood product transfusion in the post-World War II era ( 36 ) .
Recent HCV screening guidelines for individuals born during 1945 -1965 ( 17 ) combined with advances in treatment of HCV infection ( 31, 32 ) and guidelines for HCC screening and therapy ( 33 ) may accelerate progress in reducing US liver cancer mortality rates. Although 3.2 million people in the United States currently have chronic HCV infection, the rate of new infection has greatly decreased ( 17, 34 ) . Until recently, the standard of care for HCV-infected individuals consisted of lengthy treatment with interferon and ribavirin. Historically, treatment has been a challenge because of limited treatment success and discontinuation due to adverse eff ects. Progress has been made, however, and future regimens are likely to incorporate multiple direct-acting antiviral drugs. In 2011, the Food and Drug Administration (FDA) approved two direct-acting antiviral agents for individuals infected with HCV genotype 1: telaprevir and boceprevir ( 31 ) . In addition, there are other promising drugs in development that target HCV-encoded proteins. At present, prescribed drug regimens cure ~ 80 % of HCV patients. Although cost of treatment remains an impediment, developing among individuals with cirrhosis may be increasing (28) . It is plausible that a similar dynamic could also exist with respect to diabetes mellitus mortality. In summary, although overall liver cancer mortality rates increased during 2000 -2010, recent HCC incidence rates did not signifi cantly increase. Decreasing mortality rates among adult men aged 35 -49 years and Asians / Pacifi c Islanders suggest that the peak of the epidemic may be near or have passed. Findings of geographically variable liver cancer mortality rates may help target aff ected areas.
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In this study, the US liver cancer mortality rates continued a statistically signifi cant rise, whereas the increase in HCC incidence rates in SEER registries was no longer statistically signifi cant. Several factors could explain the discrepancy. Mortality statistics cover 98 % of the United States, whereas SEER registries cover 28 % , and areas with the highest mortality rates including Texas, Mississippi, and the District of Columbia are not in the SEER catchment. Underlying trends may diff er between the US and SEER areas. Second, liver cancer mortality data are based on the underlying causes of death on death certifi cates. When the cause of death is not fully documented, it can result in an undercount. Such errors are less likely with cancer incidence data that are based on detailed abstractions of medical records. Th ird, although HCC is the dominant histologic type of liver cancer, it is not the sole type, and rarer types do contribute to mortality rates. In addition, the liver is a common site of metastasis, and thus some secondary liver cancers could be mistakenly over counted as primary liver cancer. Despite these potential sources of misclassifi cation, incidence and mortality trends in SEER areas generally mirrored the US mortality trends.
As this is the fi rst year in decades during which recent HCC incidence rates did not signifi cantly increase, caution is warranted against overinterpretation. HCC incidence rates should be monitored over time to assess whether the direction of the trend turns downward, remains constant, or increases. Th e strengths of this study include the ability to examine HCC incidence in 28 % and liver cancer mortality in 98 % of the US population by age, sex, and race / ethnicity. Limitations include the absence of data on etiological risk factors. Despite limitations, the data provide insight into changes in HCC incidence and liver cancer mortality rates across demographic strata of the US population. 
